Navigation Links
Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
Date:10/14/2010

BETHESDA, Md., Oct. 14 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:00 p.m. EDT on October 21, 2010, at the New York Academy of Medicine in New York.

Dr. Marnix Bosch, Chief Technical Officer, will provide an overview of the Company's DCVax® technology and unprecedented long-term clinical trial results.

There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine.

Hosted by MD Becker Partners and BioBusiness.TV, the Cancer Immunotherapy: A Long-Awaited Reality conference includes keynote speakers, panelist and plenary sessions, company presentations, and intimate networking opportunities to meet the needs of all attendees.  Pre-registration is required and attendance is limited to 150 individuals.  To register, or to obtain more information, please visit http://www.mdbpartners.com/vaccine or contact MD Becker Partners directly at info@mdbpartners.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company has two broad platform technologies:  dendritic cell-based vaccines and therapeutic antibodies.  The Company's lead clinical trial is a 240-patient Phase II trial in GBM.  The Company also previously received clearance from the FDA for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  The Company's second technology platform, involving antibodies to CXCR4, is at the pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

About MD Becker Partners

MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry.   The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies.  As a strategic advisor and partner, MD Becker Partners provides a full range of services to help its clients increase visibility, unlock stakeholder value, and access resources to grow their business.  To accomplish this, the firm integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics.  For more information visit http://www.mdbpartners.com.

About BioBusiness.TV

BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives.  The company creates video-based, industry focused business news and analysis programs.  BioBusiness.TV produces and syndicates videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science, and more.  BioBusiness.TV's latest Original Series, "The Stem Cell Review," is a 10-part TV program on the science, medical applications, and business of stem cells, which provides a clear and concise understanding of the state of stem cells today, with the additional depth and expertise you would come to expect from the most renowned authorities in the field.  For more information, visit http://www.biobusiness.tv.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
2. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
3. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
4. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
5. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
6. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Sirius Genomics to Present at Invest Northwest Conference
10. Northwest Biotherapeutics Secures $700,000 Equity Financing
11. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... Dec. 7, 2016  Biocom, the association for the ... below following passage of 21 st Century Cures legislation ... 30 by a 392-26 vote and in the Senate on ... attributed to Joe Panetta , president & CEO of ... give hope to millions of patients around the world. The ...
(Date:12/7/2016)... Dec. 7, 2016  Vyriad Inc. announced today the ... company,s Board of Directors. "We are delighted ... our business and develop our oncolytic viruses as the ... Stephen Russell , MD, PhD, CEO of Vyriad. ... our vision and passion for making a difference for ...
(Date:12/7/2016)... Colo. , Dec. 7, 2016  Muse bio, ... engineering technologies, today announced that Dr. Kevin Ness ... of the Board of Directors. Kevin ... who becomes the company,s Chief Science Officer as well ... Executive Director of the BioDesign Center at the RAS ...
Breaking Biology Technology:
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
Breaking Biology News(10 mins):